NURS 5334 Advanced Pharmacology Final Examination
2 versions Questions and Answers | 2026 Update |
100% Correct – UTA.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Q1. A nurse practitioner is explaining pharmacokinetics to a patient. Which
statement best defines this concept?
A. The study of how drugs produce their therapeutic and adverse effects on the
body
B. The study of how the body affects drugs through absorption, distribution,
metabolism, and excretion
C. The study of drug interactions and their clinical significance
D. The study of genetic factors that influence drug response
Correct Answer: B
Rationale: Pharmacokinetics is defined as the impact of the body on drugs—
specifically, how much of an administered dose reaches its sites of action through
absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
(Option A) is the impact of drugs on the body. Options C and D describe drug
interactions and pharmacogenomics, respectively.
Q2. A patient asks the NP, "What happens to the drug after I take it?" Which
response accurately describes the four major pharmacokinetic processes?
A. Metabolism, excretion, absorption, and distribution
B. Absorption, distribution, metabolism, and elimination
C. Distribution, metabolism, excretion, and pharmacodynamics
D. Absorption, distribution, pharmacodynamics, and excretion
Correct Answer: B
Rationale: The four major pharmacokinetic processes are Absorption,
Distribution, Metabolism, and Elimination (ADME). These processes determine
,drug concentration at action sites over time. Pharmacodynamics (Options C and
D) is not a pharmacokinetic process but rather the study of drug effects on the
body.
Q3. A patient with chronic kidney disease is prescribed a medication that is
primarily renally eliminated. The NP understands that which pharmacokinetic
parameter is most affected?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Correct Answer: D
Rationale: In patients with renal impairment (chronic kidney disease), drug
elimination (excretion) is the primary parameter affected because the kidneys are
the main route of drug excretion. This requires dosage adjustments, particularly
for maintenance doses. Absorption (A) may be affected but is not the primary
concern in renal disease. Distribution (B) and metabolism (C) are more affected by
hepatic impairment or changes in protein binding.
Q4. A drug with a half-life of 8 hours is administered at regular intervals. The NP
calculates that steady-state concentration will be achieved in approximately:
A. 16 hours
B. 24 hours
C. 40 hours
D. 56 hours
Correct Answer: C
Rationale: Steady-state concentration is reached after approximately 4-5 half-
lives. With a half-life of 8 hours, 4-5 half-lives equals 32-40 hours. Option C (40
hours) represents 5 half-lives, achieving >97% of steady-state concentration.
,Option A (16 hours) is only 2 half-lives. Option B (24 hours) is 3 half-lives. Option
D (56 hours) is 7 half-lives, which exceeds the typical time required.
Q5. The NP understands that a drug reaches approximately what percentage of
steady-state concentration after four half-lives?
A. 50%
B. 75%
C. 87.5%
D. 93.75%
Correct Answer: D
Rationale: After one half-life, drug concentration is 50% of steady state. After two
half-lives, 75%. After three half-lives, 87.5%. After four half-lives, 93.75% is
achieved. This is the clinical standard for considering steady state reached. Option
A is 1 half-life. Option B is 2 half-lives. Option C is 3 half-lives.
Q6. Which of the following best describes the clinical significance of a drug's
half-life?
A. It determines the onset of action
B. It determines the time to reach steady state and dosing interval
C. It determines the route of administration
D. It determines the therapeutic index
Correct Answer: B
Rationale: Half-life determines the time to reach steady-state concentration (4-5
half-lives) and guides dosing interval frequency. It also determines the time for
drug elimination after discontinuation. Onset of action (A) is determined by
absorption rate. Route of administration (C) is influenced by drug properties but
not directly by half-life. Therapeutic index (D) relates to drug safety margin.
Q7. A drug demonstrates zero-order kinetics. The NP should expect which
elimination pattern?
, A. Elimination proportional to drug concentration
B. Elimination at a constant rate regardless of concentration
C. Elimination that increases with increasing concentration
D. Elimination that decreases as concentration increases
Correct Answer: B
Rationale: Zero-order kinetics describes elimination at a constant rate regardless
of drug concentration because elimination pathways are saturated. Examples
include phenytoin, salicylates (high dose), ethanol, and theophylline. Option A
describes first-order kinetics where elimination is proportional to concentration.
Options C and D are not characteristic of known kinetic patterns.
Q8. Which drugs exhibit zero-order kinetics at therapeutic doses?
A. Digoxin and warfarin
B. Phenytoin and salicylates
C. Metformin and insulin
D. Lisinopril and losartan
Correct Answer: B
Rationale: Phenytoin and salicylates (at high doses) exhibit zero-order kinetics.
Phenytoin has saturated hepatic metabolism, and high-dose salicylates saturate
metabolic pathways. Digoxin and warfarin (A) follow first-order kinetics.
Metformin and insulin (C) are not defined by zero-order kinetics. Lisinopril and
losartan (D) follow first-order kinetics with renal elimination.
Q9. The NP is reviewing a patient's medication list. Which drug requires careful
monitoring due to zero-order kinetics?
A. Metformin
B. Lisinopril
C. Phenytoin
D. Omeprazole
Correct Answer: C
2 versions Questions and Answers | 2026 Update |
100% Correct – UTA.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Q1. A nurse practitioner is explaining pharmacokinetics to a patient. Which
statement best defines this concept?
A. The study of how drugs produce their therapeutic and adverse effects on the
body
B. The study of how the body affects drugs through absorption, distribution,
metabolism, and excretion
C. The study of drug interactions and their clinical significance
D. The study of genetic factors that influence drug response
Correct Answer: B
Rationale: Pharmacokinetics is defined as the impact of the body on drugs—
specifically, how much of an administered dose reaches its sites of action through
absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
(Option A) is the impact of drugs on the body. Options C and D describe drug
interactions and pharmacogenomics, respectively.
Q2. A patient asks the NP, "What happens to the drug after I take it?" Which
response accurately describes the four major pharmacokinetic processes?
A. Metabolism, excretion, absorption, and distribution
B. Absorption, distribution, metabolism, and elimination
C. Distribution, metabolism, excretion, and pharmacodynamics
D. Absorption, distribution, pharmacodynamics, and excretion
Correct Answer: B
Rationale: The four major pharmacokinetic processes are Absorption,
Distribution, Metabolism, and Elimination (ADME). These processes determine
,drug concentration at action sites over time. Pharmacodynamics (Options C and
D) is not a pharmacokinetic process but rather the study of drug effects on the
body.
Q3. A patient with chronic kidney disease is prescribed a medication that is
primarily renally eliminated. The NP understands that which pharmacokinetic
parameter is most affected?
A. Absorption
B. Distribution
C. Metabolism
D. Elimination
Correct Answer: D
Rationale: In patients with renal impairment (chronic kidney disease), drug
elimination (excretion) is the primary parameter affected because the kidneys are
the main route of drug excretion. This requires dosage adjustments, particularly
for maintenance doses. Absorption (A) may be affected but is not the primary
concern in renal disease. Distribution (B) and metabolism (C) are more affected by
hepatic impairment or changes in protein binding.
Q4. A drug with a half-life of 8 hours is administered at regular intervals. The NP
calculates that steady-state concentration will be achieved in approximately:
A. 16 hours
B. 24 hours
C. 40 hours
D. 56 hours
Correct Answer: C
Rationale: Steady-state concentration is reached after approximately 4-5 half-
lives. With a half-life of 8 hours, 4-5 half-lives equals 32-40 hours. Option C (40
hours) represents 5 half-lives, achieving >97% of steady-state concentration.
,Option A (16 hours) is only 2 half-lives. Option B (24 hours) is 3 half-lives. Option
D (56 hours) is 7 half-lives, which exceeds the typical time required.
Q5. The NP understands that a drug reaches approximately what percentage of
steady-state concentration after four half-lives?
A. 50%
B. 75%
C. 87.5%
D. 93.75%
Correct Answer: D
Rationale: After one half-life, drug concentration is 50% of steady state. After two
half-lives, 75%. After three half-lives, 87.5%. After four half-lives, 93.75% is
achieved. This is the clinical standard for considering steady state reached. Option
A is 1 half-life. Option B is 2 half-lives. Option C is 3 half-lives.
Q6. Which of the following best describes the clinical significance of a drug's
half-life?
A. It determines the onset of action
B. It determines the time to reach steady state and dosing interval
C. It determines the route of administration
D. It determines the therapeutic index
Correct Answer: B
Rationale: Half-life determines the time to reach steady-state concentration (4-5
half-lives) and guides dosing interval frequency. It also determines the time for
drug elimination after discontinuation. Onset of action (A) is determined by
absorption rate. Route of administration (C) is influenced by drug properties but
not directly by half-life. Therapeutic index (D) relates to drug safety margin.
Q7. A drug demonstrates zero-order kinetics. The NP should expect which
elimination pattern?
, A. Elimination proportional to drug concentration
B. Elimination at a constant rate regardless of concentration
C. Elimination that increases with increasing concentration
D. Elimination that decreases as concentration increases
Correct Answer: B
Rationale: Zero-order kinetics describes elimination at a constant rate regardless
of drug concentration because elimination pathways are saturated. Examples
include phenytoin, salicylates (high dose), ethanol, and theophylline. Option A
describes first-order kinetics where elimination is proportional to concentration.
Options C and D are not characteristic of known kinetic patterns.
Q8. Which drugs exhibit zero-order kinetics at therapeutic doses?
A. Digoxin and warfarin
B. Phenytoin and salicylates
C. Metformin and insulin
D. Lisinopril and losartan
Correct Answer: B
Rationale: Phenytoin and salicylates (at high doses) exhibit zero-order kinetics.
Phenytoin has saturated hepatic metabolism, and high-dose salicylates saturate
metabolic pathways. Digoxin and warfarin (A) follow first-order kinetics.
Metformin and insulin (C) are not defined by zero-order kinetics. Lisinopril and
losartan (D) follow first-order kinetics with renal elimination.
Q9. The NP is reviewing a patient's medication list. Which drug requires careful
monitoring due to zero-order kinetics?
A. Metformin
B. Lisinopril
C. Phenytoin
D. Omeprazole
Correct Answer: C
